Although IBC frequently presented with higher grades and enrichment of hormone receptor-negative, HER2-positive, or triple-negative tumors, we found no statistical difference in comparing the clinicopathological parameters between the IBC and non-IBC groups. This evidence concerns the gene NR4A1 and inflammatory breast carcinoma.